{"schema_version":"secwatch.filing_event.v1","accession":"0001822479-23-000059","form_type":"8-K","ticker":"SHC","cik":"0001822479","company_name":"Sotera Health Co","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.736928+00:00","generated_at":"2026-06-09T03:08:49.390271+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sotera Health Q3 net loss of $14M; rev +6%, adj EBITDA +7%, legal settlement hit","bullets":["Q3 net loss $14M ($0.05 diluted) vs net income $25M ($0.09) a year ago; includes $35M legal settlement charge.","Net revenues rose 5.8% to $263M from $249M in Q3 2022.","Adjusted EBITDA up 7.3% to $134M; Adjusted EPS fell to $0.21 from $0.23 on higher interest expense.","Company reaffirms full-year 2023 outlook but anticipates results at the lower end of the range."],"urls":{"canonical":"https://secwatch.observer/filing/0001822479-23-000059","json":"https://secwatch.observer/filing/0001822479-23-000059.json","markdown":"https://secwatch.observer/filing/0001822479-23-000059.md","text":"https://secwatch.observer/filing/0001822479-23-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822479/000182247923000059/0001822479-23-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822479/000182247923000059/shc-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T03:08:49.390271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2fd310736c3a8f5d7a7dd8087d17056cdc37882d","claim":"Sotera Health Co reported Q3 2023 results: revenue net revenues of $263 million, net income net loss of $14 million, EPS $0.21 Adjusted EPS. Guidance reaffirmed.","evidence_excerpt":"Sotera Health Reports Third-Quarter and Year-to-Date 2023 Results • Q3 2023 net revenues of $263 million increased 6%, compared to Q3 2022 • Q3 2023 net loss of $14 million or $0.05 per diluted share, compared to net income of $25 million or $0.09 per diluted share in Q3 2022 • Q3 2023 Adjusted EBITDA of $134 million increased 7%, compared to Q3 2022 • Q3 2023 Adjusted EPS of $0.21 decreased $0.02 per diluted share, compared to Q3 2022 driven by higher interest expense • Company reaffirms 2023 outlook, anticipates results at the lower end of the range","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822479/000182247923000059/0001822479-23-000059-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q3 2023"},{"label":"Revenue","value":"net revenues of $263 million"},{"label":"Net income","value":"net loss of $14 million"},{"label":"EPS","value":"$0.21 Adjusted EPS"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}